CASE REPORT article
Front. Hematol.
Sec. Blood Cancer
Volume 4 - 2025 | doi: 10.3389/frhem.2025.1527938
Co-occurrence of AIDS and Acute Promyelocytic Leukemia: A Case Report and Review of the Literature
Provisionally accepted- 1Hangzhou City University, Hangzhou, China
- 2Yuyao People's Hospital, Yuyao, Zhejiang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Acute promyelocytic leukemia (APL) is a rare and aggressive subtype of acute myelogenous leukemia (AML), characterized by the PML-RARA fusion gene. When APL presents concurrently with acquired immunodeficiency syndrome (AIDS), it creates unique challenges in diagnosis and treatment due to the immunocompromised state of the patient. This case report describes a 46-year-old male patient with long-standing AIDS who developed APL. Initial treatment involved all-trans retinoic acid (ATRA) monotherapy due to the patient's severe lung infection and liver dysfunction, followed by the addition of arsenic trioxide (ATO) once infection and liver function improved. The patient achieved complete remission (CR) after combined ATRA and ATO therapy, with successful molecular remission of the PML-RARA fusion gene. We discuss the complexity of managing APL in the context of HIV infection, including the challenges posed by infections, liver dysfunction, and the impact of chemotherapy on antiretroviral therapy (ART). This case highlights the need for immediate initiation of ATRA in APL patients, even before genetic confirmation, and the potential therapeutic role of ATO in both leukemia treatment and HIV reservoir management.Further studies are needed to optimize treatment protocols for patients with concurrent AIDS and APL, focusing on personalized approaches to maximize efficacy while minimizing complications.
Keywords: Acute promyelocytic leukemia (APL), Acquired immunodeficiency syndrome (AIDS), All-trans retinoic acid (ATRA), Arsenic trioxide (ATO), PML-RARA fusion gene
Received: 14 Nov 2024; Accepted: 26 Jun 2025.
Copyright: © 2025 Duan, Ai, Shentu, Xu and Xia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Shiwei Duan, Hangzhou City University, Hangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.